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1. Introduction 
Epithelial ovarian carcinoma (EOC) is the fourth leading cause of cancer mortality among 
women in western countries. The incidence of newly diagnosed EOC in the US is estimated to 
be 22,430 cases per year with 15,280 deaths (Jamel A et al., 2006). Surface epithelial-stromal 
tumors are the most common neoplasms of the ovary. Their origin is likely the epithelium 
lining the ovarian surface and/or invaginations of this lining into the superficial cortex of the 
ovary. They occur in women of reproductive age and older. They are usually subclassified as 
benign, borderline and malignant. Due to the numerous histologic types of ovarian neoplasms, 
we will limit our discussion to the most common epithelial stromal tumors. We will be 
discussing the gross appearances, microscopic patterns and differential diagnosis.  
Based on the 2002 World Health Organization (WHO) classification of ovarian tumors 
(Tavassoli FA and Devilee P, 2003), Borderline and Malignant Surface-epithelial stromal 
tumors are classified as: 
1.1 WHO classification 
Serous tumors 
 Malignant  
  Adenocarcinoma 
  Surface papillary adenocarcinoma 
  Adenocarcinofibroma 
 Borderline tumor 
  Papillary cystic tumor 
  Adenofibroma and cystadenofibroma 
Mucinous tumors 
 Malignant 
  Adenocarcinoma 
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  Adenocarcinofibroma 
 Borderline tumor 
  Intestinal type 
  Endocervical type 
 Mucinous cystic tumor with mural nodules 
 Mucinous cystic tumor with pseuodomyxoma peritonei 
Endometrioid tumors including variants with squamous differentiation 
 Malignant  
  Adenocarcinoma, NOS 
  Adenocarcinofibroma 
  Malignant mullerian mixed tumor (carcinosarcoma) 
  Adenosarcoma 
  Endometrial stromal sarcoma, low grade 
  Undifferentiated sarcoma  
 Borderline tumor 
  Cystic tumor 
  Adenofibroma and cystadenofibroma 
Clear cell tumors 
 Malignant 
  Adenocarcinoma 
  Adenocarcinofibroma 
 Borderline tumor 
  Cystic tumor 
  Adenofibroma and cystadenofibroma 
Transitional cell tumors 
 Malignant 
  Transitional cell carcinoma (non-Brenner type) 
  Malignant Brenner tumor 
 Borderline  
  Borderline Brenner tumor 
Squamous cell tumors 
 Squamous cell carcinoma 
Mixed epithelial tumors 
Undifferentiated and unclassified tumors. 
2. Serous tumors 
2.1 Borderline tumors 
Serous borderline tumors (SBT) represent 25% to 30% of non benign serous tumors and 
occur in women 30-50 years of age. In the majority of cases they are unilateral and usually 
present at an early stage (stage I) (Prat J and de Nictolis M., 2002). The WHO defines SBT as 
an “ovarian tumor of low malignant potential exhibiting an atypical epithelial proliferation 
of serous type cells greater than that seen in its benign counterpart but without destructive 
stromal invasion”.  
Grossly, the mass is usually partially cystic and partially solid. Polypoid excrescences are 
present on the outer surface of the ovary or within the cyst lumen Fig.2.1.a,b.  
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Fig. 2.1.a. Borderline serous tumor (BST). The ovary shows polypoid excrescences on its 
outer surface. 
 
 
Fig. 2.1.b. BST. In another case, instead of polypoid excrescences on the outer surface of the 
ovary, papillary projections are seen within the cyst lumen of the ovary.  
The papillary structures are yellowish, soft and friable. Grossly, SBT should be 
differentiated from the hard, stocky, white excrescences that are usually a characteristic of 
serous cystadenofibroma.  
SBTs are divided into typical and micropapillary patterns.  
2.1.1 Typical SBT 
Typical SBT makes up the majority of SBT (90%). Microscopically, the papillae are lined 
by stratified cuboidal to columnar epithelial cells. These papillae show branching and 
complex structure. The epithelial cells have high nuclear cytoplasmic ratio (N/C), and the 
nuclei are hyperchromatic with prominent nucleoli. Mitotic figures are frequently present 
Fig 2.1.1 a,b.  
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Fig. 2.1.1.a. BST: At the low magnification, the tumor is composed of papillary projections.  
 
 
 
Fig. 2.1.1.b. BST: At higher magnification, the papillae are lined by epithelial cells exhibiting 
severe pleomorphism with moderate to severe atypia and with high nuclear/cytoplasmic 
ratio. They have big round nuclei and prominent nucleoli.  
Caution should be practiced when one sees what appears to be epithelial proliferation 
without cytologic atypia, because tangential sectioning of the lining of a benign serous 
cystadenoma can give the impression of proliferation of the epithelial lining.  
By definition, SBT lack stromal invasion. This is a major criterion to differentiate SBT from 
serous adenocarcinoma. Careful gross examination, as well several sections (1 section/1 cm 
of the tumor diameter) is needed. Finally, invasion of the stalk of the papillae should not be 
considered as ovarian stromal invasion. 
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2.1.2 SBT with micropapillary pattern or micropapillary SBT (MSBT) 
SBT with micropapillary pattern or micropapillary SBT (MSBT) accounts 5-10% of all 
SBTs. The significance of this subtype has generated a lot of debate in pathology. Some 
authors have found a close association between MSBT and invasive implants and urged to 
call this entity as “micropapillary serous carcinoma”. Yet others prefer the terminology of 
MSBT, avoiding the use of the term of “carcinoma”, to minimize the possibility of over 
treating patients (Chang SJ et al., 2008; Sehdev S et al., 2003). The general agreement on 
the significance of micropapillary architecture in SBTs is that there is a significant increase 
in incidence of invasive peritoneal implants (Burks R et al., 1996). Molecular studies show 
that MSBT has a similar gene expression profile as low-grade serous carcinoma (LG-
serous carcinoma) and distinct from typical SBT [May T et al., 2010]. The underlying 
genes involved in the pathogenesis of LG-serous carcinoma, and in MBST include 
mutations in a number of different genes including KRAS and BRAF.  Actually, MSBT is 
the only surface-epithelial stromal tumor with a well defined adenoma-carcinoma 
sequence, where LG serous is thought to arise in a stepwise fashion from a benign 
cystadenoma through BST to an invasive LG-serous carcinoma (Kurman RJ et al., 2008). 
Microscopically, MSBTs shows highly complex micropapillary growth in a filigree 
pattern, growing in a nonhierarchical fashion from stalk. It has been described as 
“Medusa head” like appearance. Micropapillae are at least five times as long as they are 
wide. Fig 2.1.2 a,b.  
 
 
 
 
 
 
 
Fig. 2.1.2.a. Micropapillary SBT: Microscopic examination shows highly complex 
micropapillary growth in a filigree pattern, which is defined by a growth in a 
nonhierarchical fashion from fibrous stalk forming what we say “Medusa head’ like 
appearance. 
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Fig. 2.1.2.b. Micropapillary SBT: The micropapillae are at least five times as long as they are 
wide. 
Micropapillary foci should occupy an area of at least 5 mm, since micropapillary foci of less 
than 5 mm have no bearing on clinical outcome (Slomovitz MB et al., 2002).  
2.1.3 Peritoneal implants 
Peritoneal implants are classified into epithelial invasive and non-invasive implants, and 
desmoplastic invasive and non-invasive implants. Implants are a hetergenous group and 
various types may coexist, therefore, multiple biopsies of numerous foci of suspicious 
lesions at the time of surgery and extensive tumor sampling by the pathologist, is the main 
key to exclude an invasive implant. 
Epithelial non-invasive implants are characterized by the presence of branching, complex 
papillae within cystic spaces with no stromal reaction or destruction Fig 2.1.3.a. 
 
 
Fig. 2.1.3.a. Non-invasive peritoneal implant: The implant is defined by papillary structure 
in a space like structure with no evidence of invasion or destruction of the ovarian stroma. 
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SBT with non-invasive implants have been considered indolent, with 5-year survival rate of 
95% and recurrence rate ranging from 8% to 32% (Silva EG et al., 2006). 
Epithelial invasive implants are characterized by haphazardly distributed glands and 
clusters of branching papillae infiltrating the adipose tissue and stroma. The epithelial cells 
should have marked cytologic atypia. The associated stroma is composed of dense fibrous 
tissue Fig 2.1.3.b. Patients with SBT with invasive implants may develop low grade 
carcinomas many years after initial diagnosis. (McCluggage WG, 2010) 
 
 
Fig. 2.1.3.b. Invasive implant: it is defined by complex structure of papillae where the 
neoplastic cells exhibit severe cytologic atypia and they seem to infiltrate a very dense stroma. 
Desmoplastic non invasive implants are defined by clusters of tumor cells that are present 
in a loose fibrous stroma. The stroma may have granulation tissue like features with 
neutrophilic infiltrates and hemorrhage. 
Differential diagnosis: Implants should be distinguished from benign epithelial inclusions or 
endosalpingiosis. Inclusions are defined by small glands lined by a single cell layer without 
atypia. Endosalpingiosis is characterized by a lining typical for tubal epithelium such as 
ciliated and intercalated cells. 
2.1.4 SBT with microinvasion 
Microinvasion is defined as single cells or few clusters of cells similar to those seen in the 
overlying SBT that infiltrate the stroma. One or more foci may be present but none should 
exceed 10 mm2. SBT with microinvasion appears to have no significance on disease 
outcome, with 10 year survival rate is of 86% (Slomovitz BM et al, 2002). 
2.1.5 Implants in a lymph node  
Approximately 27% of surgically staged patients with SBT present with lymph node 
involvement by tumor. The most common lymph nodes involved are the pelvic and paraaortic 
groups. Recent molecular and morphologic data suggest that although most nodal implants 
are indeed metastatic from a concurrent ovarian neoplasms, small subsets arises de novo from 
nodal endosalpingiosis. It has also been suggested that the route of spread from an ovarian 
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SBT to lymph nodes might be via a peritoneal route and not lymphatic. The morphology of the 
implant is similar to that occurring in the ovary. Lymph node involvement does not adversely 
impact the overall survival of patients with SBT of the ovary [Fadare O, 2009]. The major 
differential diagnosis is endosalpingiosis and the criteria are cited previously in the text. 
2.2 Serous carcinoma 
Serous adenocarcinoma occurs in women a bit older than women with SBT, with an average 
age of 56 years. Patients with serous adenocarcinoma often present with advanced stage 
disease (stage III and IV) at first presentation.  
Grossly, the tumor varies considerably in size from a few cm to 30 cm. The cut surface may 
be partially cystic and partially solid or it may be solid with areas of necrosis and 
hemorrhage Fig 2.2.a. When infiltrating the omental adipose tissue, the tumor creates what 
is called “omental caking” Fig 2.2.b.  
 
 
Fig. 2.2.a. Serous adenocarcinoma: the ovarian mass is solid with few cystic areas. The cut 
surface is firm, white with areas of necrosis and hemorrhage.  
 
Fig. 2.2.b. Omentum: The tumor involves the omentum and create “omental cake” which is 
characterized by tumoral seeding of the adipose tissue. The cut surface is white, firm and 
homogenous.  
www.intechopen.com
 Borderline and Malignant Surface Epithelial –Stromal Tumors of the Ovary 
 
63 
2.2.1 Grading 
Grading of surface epithelial stromal tumors is still performed haphazardly with several 
systems and non-systems used in different institutes and in different research studies. The 
lack of uniformity in grading has resulted in little consensus as to whether ovarian tumor 
grade has any significance in predicting disease outcome. The grading systems used most 
commonly worldwide are the International Federation of Gynecology and Obstetrics (FIGO) 
system, and the World Health Organization (WHO) system. The FIGO grading system for 
the ovary is similar to the grading system used in the uterus. It is based on architectural 
features. The grade depends on the ratio of glandular or papillary structures versus solid 
tumor growth. Grade 1 is equivalent to <5% solid growth, grade 2 to 5-50% solid growth 
and grade 3 to =>50% solid growth (International federation of Gynecology & Obstetrics, 
1971). In the WHO system, the grade is assessed by both the architectural and cytologic 
features, without any quantitative values (Tavassoli FA and Devilee P., 2003). The 
Gynecologic Oncology (GOG) system is the most commonly used system in the United 
States (Benda JA et al., 1994). It employs a method based on the histologic type. For 
example, ovarian carcinoma of endometrioid type is graded similarly to the endometrial 
adenocarcinoma of endometrioid type. Ovarian carcinoma of transitional type is graded 
similar to transitional cell carcinoma (TCC) of the bladder. Clear cell carcinomas are not 
graded at all. Silverberg’s et al proposed a new grading system similar to that used in breast 
carcinoma and it depends on architectural features (glandular 1, papillary 2 and solid 3), 
cytologic atypia (mild 1, moderate 2, severe 3), and mitotic rate (1 0-9 mitosis/10HPF, 2 10-
24, 3 >25). A score is given by adding the parameters, a score of 3-5, is grade 1, a score of 6-7 
is grade 2, and a score of 8 -9 is grade 3 (Silverberg S, 200). Fig 2.2.1a and Fig 2.2.1.b are 
examples of grade 1 and grade 3 serous carcinomas.  
 
 
 
 
 
 
Fig. 2.2.1.a. Low grade serous carcinoma: The tumor has papillary features. The neoplastic 
cells have mild to moderate atypia and rare mitotic figures. 
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Fig. 2.2.1.b. High grade serous carcinoma: The tumor cells are arranged in solid sheets with 
very rare foci of papillary architecture. The cells exhibit severe atypia and frequent mitotic 
figures.  
This grading system was confirmed to be reproducible in subsequent studies (Ishioka SI et 
al., 2002). Another study from MD Anderson cancer center group suggested adopting a two-
tier system that is based primarily on the assessment of nuclear atypia (uniformity vs. 
pleomorphism) in the worst area of the tumor (Malpica A et al., 2004). The tumor is graded 
into low grade and high grade. A few years after its introduction, the authors confirmed its 
reproducibility and urged its use to facilitate the clinical trials and protocols (Malpica A et 
al., 2007).  
3. Mucinous tumors 
3.1 Mucinous borderline tumors 
Mucinous borderline tumors (MBT) (mucinous tumors of low malignant potential) as 
defined by the WHO, are tumors exhibiting an epithelial proliferation of mucinous type 
cells greater than that seen in their benign counterparts but without evidence of stromal 
invasion. MBT can be of intestinal type or endocervical-like type.  
3.1.1 Mucinous borderline tumors of intestinal type 
The intestinal type tumors are the most common type of MBTs, accounting for 85-90% of 
cases. They are not associated with peritoneal implants or lymph node involvement. Similar 
to low- grade serous tumors, intestinal type MBTs are thought to arise from a cystadenoma 
and to progress to carcinoma, following the adenoma-carcinoma sequence model. Grossly, 
they are usually a very large unicystic or multicystic mass filled with mucoid-gelatinous 
material Fig 3.1.1a.  
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Fig. 3.1.1.a. Mucinous borderline tumor (MBT): The cut surface of the ovarian mass shows 
multiple cysts filled with gelatinous material. However in some areas the wall of the cyst 
seemed to be thickened. 
Histologically, the lining of the cyst is composed of stratified lining of epithelial cells having 
high N/C ratio and prominent nucleoli Fig 3.1.1.b,c. Goblet cells and Paneth cells are 
present. No stromal invasion is seen.  
 
 
 
 
Fig. 3.1.1.b. MBT: At low magnification, the tumor is composed of proliferation of glands 
which some are cystically dilated separated by abundant intervening stroma.  
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Fig. 3.1.1.c. Higher magnification showed that the glands are lined by mucin secreting cells 
exhibiting moderate to severe atypia, big nuclei and prominent nucleoli. In some areas, the 
cytoplasm shows mucin depletion. Mitotic figures are frequently present.  
3.1.2 Mucinous borderline tumors of endocervical type 
The endocervical type tumors are a less common and make up 10-15% of MBTs. They are 
usually smaller in size than their intestinal type counterparts and they are commonly 
bilateral (40%). They are thought to arise from endometriosis. Microscopically, the epithelial 
cells lining the cyst wall contain intracytoplasmic mucin, resembling endocervical cells.  
3.1.3 Mucinous tumors with mural nodules 
Mucinous tumors of the ovary, whether benign, borderline or malignant, may contain one or 
more nodules. These nodules are morphologically different than the overlying mucinous 
neoplasm. Grossly, nodules are yellow, pink with areas of hemorrhage and necrosis Fig 3.1.3.a.  
 
 
Fig. 3.1.3.a. Mural nodules: Mural nodules are grossly characterized by a well defined mass 
within the wall of the cyst. The cut surface is often hemorrhagic.  
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Microscopically, the mural nodules may be malignant (anaplastic, sarcoma or 
carcinosarcoma) or benign (sarcoma-like). It is important to distinguish between benign and 
malignant mural nodules, because benign mural nodules are of no prognostic significance. 
Immunohistochemistry is a very helpful tool for this purpose. Sarcoma-like nodules are 
composed of a heterogenous cell population of cells including spindle cells, giant cells, 
mononuclear cells and inflammatory cells. The cells of the sarcoma- like nodules are 
negative or very weakly positive for cytokeratin Fig3.1.3.b.  
 
 
Fig. 3.1.3.b. Sarcoma-like nodules: They are composed of heterogenous cell population 
including spindle cells, giant cells, mononuclear cells and inflammatory cells.  
Anaplastic sarcoma mural nodules are composed of diffuse sheets of spindled or large 
rhabdoid-looking cells with abundant eosinophilic cytoplasm and prominent nucleoli fig 
3.1.3.c,d. These cells are usually strongly positive for cytokeratin fig 3.1.3.e.  
 
 
Fig. 3.1.3.c. Anaplastic nodules: They are characterized by proliferation of spindle cells. 
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Fig. 3.1.3.d Anaplastic nodules: At higher magnification, the spindle cells exhibit severe 
atypia, hyperchromasia and numerous mitoses.  
 
 
 
Fig. 3.1.3.e. Anaplastic nodules: The spindle cells in are strongly positive for total 
cytokeratin immunostain.  
Lastly Sarcoma nodules exhibit a variety of patterns such as fibrosarcoma, 
rhabdomyosarcoma and undifferentiated sarcoma.  
3.2 Mucinous adenocarcinoma 
Mucinous adenocarcinomas (MAC) are very large tumors; many are 15 to 30 cm in diameter 
and weigh as much as 4 kgs. The cut surface can be cystic or solid and the content is 
composed of gelatinous, mucoid material Fig 3.2a.  
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Fig. 3.2.a. Mucinous cystadenocarcinomas: Grossly, they are characterized by partially cystic 
and partially solid mass. The cysts content is composed of gelatinous material. 
These tumors are defined by invasion and adequate sampling is a key factor to document 
invasion process. Numerous sections (2 to 3 sections /1cm of tumor diameter) are required. 
Invasion can be defined as infiltration of ovarian stroma by neoplastic cells arranged in nests 
or as single cells with a stromal desmoplastic reaction Fig 3.2.b,c.  
 
 
 
 
 
Fig. 3.2.b. Mucinous adenocarcinoma: It is also defined by proliferation of back to back 
glands with no or little interfering stroma.  
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Fig. 3.2.c. Mucinous adenocarcinoma: These glands are cytologically malignant with severe 
atypia, large nucleoli, loss of cytoplasmic mucin and numerous mitosis.  
However, one needs not to see typical stromal invasion with desmoplastic reaction to 
diagnose MAC, because invasion can also be defined as neoplastic glands which are back to 
back with no intervening stroma Fig 3.2d. Similar to MBTs, the epithelial lining in MAC can 
be of intestinal or endocervical type. MAC should be distinguished from metastatic 
adenocarcinoma from colonic origin. Metastatic colonic carcinomas are usually bilateral. 
Morphologically, they are characterized by glandular proliferation with abundant dirty 
necrosis and nuclear debris within amorphous necrotic tissue. The glands are lined by 
stratified cells with prominent atypia and mitosis Fig 3.2.e 
 
 
 
Fig. 3.2.d. Mucinous cystadenocarcinoma: It is defined by invasion of the ovarian stroma by 
small glands and nests of tumor cells .  These glands are cytologically malignant and 
infiltrate the stroma in disorderly fashion. 
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Fig. 3.2.e. Metastatic colon carcinoma: It is characterized by large glands with center “dirty” 
necrosis and nuclear debris within amorphous necrotic tissue. 
3.3 Pseudomyxoma peritonei 
Pseudomyxoma peritonei (PP) is a clinical term used to describe the finding of mucoid, 
gelatinous material in the abdominal cavity, often accompanied by an ovarian or 
gastrointestinal tumor. In 1995, Ronnett et al classified PP into low-grade variety “diffuse 
peritoneal adenomucinosis” (DPAM) and to high-grade variety “peritoneal mucinous 
carcinomatosis” (PMCA) (Ronnett BM et al, 1995). DPAM is defined as pools of mucin with 
few strips of mucinous epithelium exhibiting minimal cytologic atypia and rare mitotic 
figures Fig3.3.a. On the other hand, PMCA is characterized by abundant mucinous 
epithelium, glands or signet ring cells, showing severe atypia which are clearly malignant 
Fig3.3.b.  
 
 
Fig. 3.3.a. Peritoneal mucinosis; It is characterized by pool of acellular mucin.  
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This classification is prognostically significant with 5-year survival rates of 84% for DPAM 
and 6.7% for PMCA (Ronnett BM et al, 2001).  PP may originate from an ovarian primary or 
from an appendiceal primary. An appendectomy is necessary in those circumstances. 
Grossly, the appendix shows a dilated lumen filled with mucinous material. Histologically, 
depending upon the cytologic atypia, the appendiceal tumor may be a mucinous 
adenocarcinoma or a mucinous tumor of low malignant potential Fig3.3.c,d. (Misdraji J, 
2009).  
 
 
 
Fig. 3.3.b. Peritoneal adenocarcinomatosis: It is characterized by pool of mucin and clusters 
of malignant cells with signet-ring features. 
 
 
 
Fig. 3.3.c. Appendiceal mucinous tumor: The appendiceal lumen is dilated and filled with 
mucin which is dissecting the entire thickness of the wall. 
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In many cases, the appendix is encased by a very large mucinous mass, and histologically, 
the appendix is replaced by tumor, rendering the diagnosis of appendiceal primary very 
difficult.  
 
 
Fig. 3.3.d. Appendiceal mucinous tumor: The appendiceal mucosa shows proliferation of 
mucin-secreting cells that they are not frankly malignant. Due to the absence of glandular 
cribriform and submucosal invasion, this lesion is classified as mucinous tumor of low 
malignant potential. 
Not so long ago, there was a considerable controversy about the origin of mucin in PP, in 
women with concomitant mucinous tumors of the appendix and the ovaries. Recent 
immunohistochemical, molecular, and genetic evidence supports the appendix as the 
primary tumor and secondary involvement of the ovary (Ronnet BM et al, 2004)  In difficult 
cases, immunohistochemistry study including cytokeratin 7 (CK7), cytokeration 20 (CK20) 
and CDX2 are useful to discriminate between primary appendix from primary ovarian 
mucinous tumors. At first CDX2 seemed to be a promising marker and its positivity was 
found to be very specific for lower gastrointestinal carcinomas but as more studies have 
been published, more cases of ovarian mucinous tumors have been found to be positive for 
CDX2 rendering its use of little value. On the other hand CK7/CK20 is more useful, as 
ovarian mucinous tumor are CK7+/CK20+ and appendiceal/ colon tumors are CK7-
/CK20+. Thus, CK7/CK20 is the most useful and reliable combination in distinguishing 
appendiceal versus ovarian primary (Chu P et al., 2000; Kaimaktchiev et al., 2004).  
4. Endometrioid tumors 
4.1 Endometrioid adenocarcinoma 
Endometrioid adenocarcinoma (EAC) account for 10-20% of ovarian carcinomas. They 
occur in postmenauposal women, with average age of 56 years. The frequent association 
with endometriosis and endometrioid adenocarcinoma of the endometrium suggested 
that some EAC of the ovary might have the same risk factors as those occurring in the 
endometrium.  In contrary to serous carcinomas, about half of EAC cases present as early 
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stage disease (stage I and II). They are bilateral in 20% of cases. Microscopically, these 
tumors are usually well differentiated tumors (grade I). The tumor is microscopically very 
similar to those occurring in the endometrium, where back to back glands with no 
intervening stroma and squamous differentiation in the form of squamous morules and 
keratin pearls are present. Fig 4.1a., b 
 
 
Fig. 4.1.a. Endometrioid adenocarcinoma (EAC): The morphologic features of this tumor are 
very similar to those occurring in the endometrium where back to back glands with no 
intervening stroma.  
 
Fig. 4.1.b. EAC: The glands are cribriform and they are cytologcially malignant. 
Rare examples of mucin-rich, secretory, ciliated, and oxyphilic types have been described. 
Occasionally the tumor may resemble granulosa cell tumor, with the cells arranged in 
ribbons, and small glands, creating the illusion of Call-Exner bodies. Also, rare cases exhibit 
tubular glands resembling a Sertoli-Leydig cell tumor. In both cases alpha-inhibin is 
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excellent marker to differentiate between EAC and sex-cord tumors, where it is negative in 
EAC of the ovary and it is positive in sex-cord stromal tumors such as Sertoli-Leydig tumors 
and granulosa cell tumors Fig 4.1.c.d  (Zhao C et al., 2007; Pelkey TJ et al., 1998). 
 
 
 
Fig. 4.1.c.  Sertoli-Leydig cell tumor: They may be arranged in irregular tubules lined by 
stratified epithelium resembling endometrial adenocarcinoma. 
 
 
 
Fig. 4.1.d. Sertoli-Leydig cell tumor: Tumor cells are positive for inhibin immunostain. 
4.2 Carcinosarcoma (mixed malignant mullerian tumor/MMMT) 
Carcinosarcomas account for <1% of all ovarian cancers and occur in the sixth to eight 
decades. They are composed of two components; a malignant epithelial component and 
sarcomatous elements. The sarcomatous component may be homologous (tissue native to 
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the ovary) or heterologous elements (skeletal muscle, cartilage and bone). Molecular studies 
support a clonal origin of both components, leading some to propose designating 
carcinosarcoma as a “metaplastic carcinoma” (Thompson L et al, 1996; Mayall F et al, 1994). 
The epithelial component is usually of endometrioid type adenocarcinoma but other types 
like serous or mucinous may be found Fig 4.2.a. The sarcomatous component may be a 
homologous type such as fibrosarcoma, high-grade endometrial stromal sarcoma, or a 
heterologous type including chondrosarcoma or rhabdomyosarcoma Fig 4.2.b.  
 
 
 
Fig. 4.2.a. MMMT: the tumor is composed of two components which are malignant, the 
epithelial component (adenocarcinoma) and the mesenchymal component (sarcoma). 
 
 
 
Fig. 4.2.b. MMMT: the mesenchymal component (sarcoma) is composed of very atypical, 
hyperchromatic cells. These cells have a high mitotic rate.    
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5. Clear cell tumors 
Clear cell carcinoma 
Clear cell carcinomas (CCC) represent 6% of surface-epithelial tumors. They occur in 
postmenopausal women, with a mean age of 57 years. CCC of the ovary has a few notable 
characteristics 1- they are almost always unilateral, 2- they are admixed with 
endometrioid type adenocarcinoma in 20-25% of cases, 3- they are often accompanied by 
endometriosis of the same ovary, 4- they may be associated with paraneoplastic 
hypercalcemia and 5- they have frequent mutations of ARID1A and PIK3CA genes 
(Anglesio MS et al., 2011). Histologically, CCC may exhibit various patterns of growth, 
including tubulo-cystic, papillary and solid patterns Fig 5.a. The papillae of CCC are 
unique in that they are composed of an extensive hyaline core which is different from the 
small, fibrovascular core papillae as seen in serous adenocarcinoma. In addition, CCC can 
display numerous cell types such as clear, hobnail, cuboidal, flat, oxyphilic and signet-cell 
types. The most common type, clear cell type, is defined by round to polygonal cells with 
a clear cytoplasm, eccentric nuclei and prominent nucleoli Fig5.b, c. The cytoplasm 
contains abundant glycogen which is Periodic acid-Schiff (PAS) positive, diastase 
digestion resistant. Numerous intracytoplasmic hyaline globules may be seen. Mucin can 
be found in the lumens of tubules and cysts and it is very abundant in the cytoplasm of 
the signet ring cell types.  
 
 
 
 
 
 
 
 
 
Fig. 5.a. Clear cell carcinoma (CCC): low magnification shows proliferation of neoplastic 
cells in form of solid sheets and papillary patterns. 
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Fig. 5.b. CCC: The cells have a clear cytoplasm, and eccentrically located round nuclei.  
 
 
 
 
 
 
Fig. 5.c. CCC: some cells contain inspissated secretion that is mucicarmine positive creating 
a targetoid appearance.  
Due to these various patterns, CCC can be mistaken for germ cell tumors including 
dysgerminoma, yolk sac tumors, endometrioid adenocarcinoma with secretory changes, and 
with metastatic renal cell carcinoma (RCC) Fig 5.d,e.  
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Fig. 5.d. Yolk sac tumor: The tumor is arranged in a loose stroma with small cystic structures. 
 
 
 
 
Fig. 5.e. Yolk sac tumor: The tumor cells have abundant eosinophilic cytoplasm and contain 
hyaline bodies.  
Alpha-fetoprotein (AFP), placenta alkaline phosphatse (PLAP), cytokeratins and epithelial 
membrane antigen (EMA) are helpful immunohistochemistry stains to distinguish CCC 
from germ cell tumors. In germ cell tumors, AFP and PLAP are positive and cytokeratin and 
EMA are negative, while CCC cells are negative for AFP and PLAP and positive for 
cytokeratin and EMA (Mittal k et al 2008).  
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Metastatic RCC to the ovary, though rare, creates a major diagnostic challenge, when CCC 
of the ovary is of clear cell type. It is almost impossible to differentiate the two based solely 
on morphology. Therefore, IHC is helpful as RCC is usually negative for CK7 and positive 
for CD10 and CCC of the ovary is typically positive for CK7 and negative for CD10. In 
addition, correlation with radiologic findings is necessary to rule out metastatic RCC (Mittal 
K et al, 2008).  
6. Transitional cell tumors 
Transitional cell carcinoma and malignant Brenner tumors 
The group of transitional cell tumors includes benign Brenner tumors, borderline and 
malignant Brenner tumors, and transitional cell carcinoma. By definition, transitional cell 
carcinoma of the ovary (TCC-O) and malignant Brenner tumors are composed of epithelial 
cells morphologically resembling urothelium. TCC-O is the least common surface epithelial 
tumor of the ovary, accounting 1-2% of all ovarian tumors. It may sometimes be associated 
with germ cell tumors. They are bilateral in 15% of the cases. Grossly they are cystic with 
intracystic papillary projections Fig 6.a.  
 
 
 
 
 
 
 
Fig. 6.a. Transitional cell carcinoma of the ovary (TCC-O): The mass is mostly composed of 
one large cystic where a large vegetating tumoral mass protrudes in the lumen. 
TCC-O can be already widespread disease at the time of diagnosis, however, malignant 
Brenner tumors are usually stage I disease at first presentation.  Histologically, TCC-O and 
malignant Brenner tumors resemble TCC occurring in the urinary tract. They are composed 
of papillary projections protruding into a cystic lumen, lined by multilayered malignant 
transitional epithelium Fig 6.b.c. 
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Fig. 6.b. TCC-O: The tumor is composed of broad undulating macropapillae with smooth 
borders. 
 
Fig. 6.c. TCC-O: At higher magnification, the macropapillae are composed of multilayered 
transitional cells resembling that of papillary transitional cell carcinoma of the bladder. 
These cells have high grade nuclei and numerous mitotic figures. 
Foci of glandular differentiation and squamous metaplasia may also be seen. Very often, 
TCC can be mixed with serous adenocarcinoma. At matched stage, TCC-O has a worse 
prognosis compared to malignant Brenner tumors. Therefore, TCC-O should be 
differentiated from malignant Brenner tumors. Morphologically, TCC-O lack an associated 
benign or borderline Brenner tumor, whereas, malignant Brenner tumors are always 
accompanied by benign or borderline Brenner tumors (Eichhorn JH et al., & Young RH, 
2004). Thus, extensive tumor sampling is needed to make an accurate diagnosis. The major 
differential diagnosis is metastatic TCC from the urinary tract and immunohistochemistry 
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can be very helpful. Numerous studies have dealt with this issue and concluded that the 
best IHC panel is CK20, uroplakin, and Wilm’s tumor (WT). TCC-O are CK20-, uroplakin- 
and WT1+, whereas, metastatic TCC from the bladder are CK20+, Uroplakin + and WT1- ( 
Logani S et al., 2003; Delair D et al., 2011 ; Ordonez NG, 2000). 
7. Squamous cell carcinoma 
Squamous cell carcinomas (SCCs) of the ovary are very rare. They arise most commonly 
from the lining of a dermoid cyst, endometrioisis or a Brenner tumor (Acien P et al, 2010; 
Bal A et al, 2007). They have similar morphology to squamous cell carcinoma occurring in 
the cervix or vagina. Fig 7.a   
 
 
Fig. 7.a. Squamous cell carcinoma. Tumor cells are arranged in large nests. Keratin pearls 
and necrotic debris is also present. The tumor cells resembling squamous cell carcinoma of 
the cervix or squamous cell carcinoma of any origin.  
Before the diagnosis of primary squamous cell carcinoma of the ovary is made, metastatic 
SCC from the cervix should be excluded. In addition, primary SCCs of the ovary should be 
distinguished from endometrioid adenocarcinoma with extensive squamous differentiation. 
Thus, extensive sampling is recommended. Cases of primary SCCs of the ovary frequently 
have spread beyond ovary at the time of presentation, leading to poor prognosis.  
8. Ovarian carcinoma after neoadjuvant therapy 
Traditionally, advanced stage ovarian carcinoma is treated by debulking surgery followed 
by chemotherapy. In some circumstances, neoadjuvant chemotherapy followed by 
debulking surgery may be done. Neoadjuvant chemotherapy is increasingly being used in 
the management of patients with advanced ovarian cancer and pathologists should be 
aware of the morphologic changes in ovarian cancer after neoadjuvant chemotherapy. For 
the inexperienced or those with no knowledge of the patients’ history, treated tumors may 
be mistaken for metastatic carcinoma from breast primary or other sites. The morphologic 
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changes seen in response to neoadjuvant chemotherapy include small groups or single 
tumor cells in a densely fibrotic stroma Fig 8.a. The tumor cells are characterized by 
nuclear and cytoplasmic alteration making the grading and sometimes the tumor typing 
impossible and inaccurate. Nuclear changes include nuclear enlargement, 
hyperchromasia, irregular nuclear outlines and chromatin smudging. Cytoplasmic 
alterations include eosinopholic cytoplasm, vacuolation and foamy cell changes Fig 8.b. 
The stroma may have pronounced fibrosis, inflammation, foamy histiocytic infiltrates, 
hemosiderin deposits, necrosis, calcification and numerous free psammoma bodies 
(McCluggage WG et al., 2002; Chew I et al., 2009).  
 
 
Fig. 8.a. Ovarian carcinoma after neoadjuvant therapy: The tumor presents extensive areas 
of fibrosis with few areas of remaining viable tumor cells. 
 
 
Fig. 8.b. Ovarian carcinoma after neoadjuvant therapy  The nuclear changes seen including 
nuclear enlargement, hyperchromasia, irregular nuclear outlines and chromatin smudging.  
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The immunohistochemistry profile is similar to that of native untreated tumors. Ck7, 
CA125, WT1, ER, p53 and p16 may be of value in identifying residual tumor cells [Miller 
K et al., 2008].  
9. Conclusion 
Ovarian tumors are often complex and heterogenous in nature. In this book chapter we 
limited our discussion to the most common ovarian tumors in adult women. This is a 
concise histological description of these tumors that clinicians will find useful in their daily 
practice.  
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